JNJ - Johnson & Johnson
| Previous close | 141.34 |
| Open | 141.10 |
| Bid | 141.39 x 1000 |
| Ask | 141.51 x 1100 |
| Day's range | 140.31 - 141.80 |
| 52-week range | 121.00 - 144.98 |
| Volume | 3824826 |
| Avg. volume | 7,199,685 |
| Market cap | 372B |
| Beta (5Y Monthly) | 0.70 |
| PE ratio (TTM) | 26.97 |
| EPS (TTM) | 5.24 |
| Earnings date | 22 Jan 2020 |
| Forward dividend & yield | 3.80 (2.69%) |
| Ex-dividend date | 2019-11-25 |
| 1y target est | 150.78 |
Reuters VideosWall Street rebounds on trade hopes
Stocks on Wall Street rose for the first time in four sessions Wednesday. Spurring them higher: President Donald Trump's remarks that trade talks with China were going "very well." Energy stocks led the broad-based rally, pushing the S&P 500 up more than half percent. Edward Jones investment strategist, Nela Richardson: SOUNDBITE: EDWARD JONES INVESTMENT STRATEGIST, NELA RICHARDSON (ENGLISH) SAYING: "Investors should expect more volatility. So more of the same next year. It doesn't wash away with an interim deal or a tweet or a change in rhetoric. What investors should look for is actual change in actions like a removal or roll back of the existing tariffs and no new tariffs." Shares of online travel agency Expedia among the biggest gainers on the S&P 500. Its CEO and finance head resigned after clashing with the board over strategy. Johnson & Johnson helped lift the Dow. The drug maker said recent tests showed its Baby Powder was free of asbestos. Earlier this year, the FDA reported trace amounts of the material in the product. Shares of Alphabet rallied. Google CEO Sundar Pichai will immediately take over as CEO of the parent company now that Larry Page and Sergey Brin are stepping aside.
- Zacks
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
Johnson & Johnson (JNJ) closed at $139.99 in the latest trading session, marking a -0.36% move from the prior day.
- Reuters
J&J CEO spurns U.S. congressional hearing on carcinogens in talc products
In an announcement, the House of Representatives Subcommittee on Economic and Consumer Policy said that its efforts to persuade Gorsky to testify included "repeated attempts to accommodate the company" over nearly a month. Democrat Raja Krishnamoorthi, chairman of the House panel investigating concerns about cancer-causing asbestos in cosmetic talc and powders, said he was disappointed Gorsky turned down the invitation. "Mr. Gorsky refuses to speak to the Subcommittee under oath, yet he has not refrained from making multiple public comments on the topic," Krishnamoorthi said in a statement.
- Zacks
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
- Zacks
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
- Zacks
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
- Zacks
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
- Zacks
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
- Zacks
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $139.38, moving +1.62% from the previous trading session.
- Zacks
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
- Zacks
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
- Reuters
J&J says new tests show no asbestos in Johnson's Baby Powder
A total of 155 tests were conducted by two different third-party labs using four different testing methods on samples from the same bottle tested by the FDA's contracted lab, the company said. The tests are the latest effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of Johnson's Baby Powder in October.
- Reuters
Special Report - Powder Keg: FDA bowed to industry for decades as alarms were sounded over talc
The “Asbestos in Talc Symposium,” sponsored by the Food and Drug Administration, was dominated by industry hands: Most of the 21 non-government participants had done work for talc companies, such as testing and serving as expert witnesses and consultants, symposium documents and other records show. Key sessions were led by witnesses for Johnson & Johnson in lawsuits alleging the company failed to warn customers that its Baby Powder was tainted with cancer-causing asbestos, the records show. Over the past 50 years, the FDA has relied upon - and often deferred to - industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
- Yahoo Finance
The uniquely American opioid crisis, in 3 charts
And according to data from Deutsche Bank Research, opioid-related deaths per million inhabitants has drastically increased in the U.S. compared to the other Organization for Economic Cooperation and Development (OECD) countries.
- Zacks
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- Zacks
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
Style Box ETF report for IWX
- Zacks
Fed Reportedly Opens Criminal Investigation on Opioid Makers
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
- Yahoo Finance
Stock Market Live Updates: Markets close at record highs
Headlines moving the stock market in real time.
- Yahoo Finance
Why mental health coverage is still a struggle for employer-sponsored plans
New report sets stage for greater mental health coverage.
- Investing.com
NewsBreak: Trump Looks to Let Florida, Others Import Prescription Drugs
Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.
- Associated Press
Oklahoma attorney general to appeal judge’s opioid ruling
Oklahoma Attorney General Mike Hunter says he plans to appeal a judge’s order directing consumer products giant Johnson & Johnson to pay the state $465 million to help address the state’s opioid crisis. Hunter said Thursday the judge’s final order only covers one year of the state’s proposed abatement plan and that the actual costs to clean up the damage from the opioid crisis are much higher. Johnson & Johnson had asked the judge to consider reducing the final award based on pre-trial settlements totaling $355 million the state reached with other defendants in the case.
- Reuters
Johnson & Johnson loses pelvic mesh class action in Australia
More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants. The suit is one of many J&J has faced in the United States, Canada and Europe over the implants, used to treat urinary incontinence and pelvic organ prolapse, in which organs shift from normal positions. J&J in October agreed to pay nearly $117 million to resolve claims in 41 U.S. states and the District of Columbia.
- Zacks
Myovant Up on Successful Completion of Prostate Cancer Study
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
